Please login to the form below

Not currently logged in
Email:
Password:

Cosentyx

This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Novartis’ Cosentyx can put some of its fast growth in psoriasis down to data showing it was more effective than Johnson &Johnson’s widely-used Stelara, but a new trial has ... In a head-to-head challenge, J&J’s recently approved follow-up to

Latest news

More from news
Approximately 22 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    An Outcomes Guarantee model - Cosentyx promise. Among the many initiatives Novartis is working on with the NHS is ‘The Cosentyx Promise’. ... Cosentyx is the company's psoriasis treatment, and Novartis supplies the drug with an outcomes guarantee.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’ contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics